TransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price objective increased by research analysts at Oppenheimer from $130.00 to $150.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's price target points to a potential upside of 6.69% from the stock's previous close.

Several other analysts have also recently weighed in on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday. Finally, Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Stock Down 1.0%

Shares of TMDX stock traded down $1.36 during trading on Tuesday, reaching $140.60. The company's stock had a trading volume of 205,245 shares, compared to its average volume of 1,356,272. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The stock's 50-day moving average price is $110.23 and its 200 day moving average price is $82.77. The company has a market capitalization of $4.76 billion, a price-to-earnings ratio of 149.71 and a beta of 2.10. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 earnings per share. On average, research analysts anticipate that TransMedics Group will post 1 EPS for the current year.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director now owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in TMDX. NBC Securities Inc. purchased a new stake in TransMedics Group during the 1st quarter valued at approximately $25,000. Smartleaf Asset Management LLC increased its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares during the period. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group during the fourth quarter worth approximately $31,000. Quarry LP lifted its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the period. Finally, Hager Investment Management Services LLC lifted its holdings in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.